Design Therapeutics (DSGN) Cash from Operations (2020 - 2026)
Design Therapeutics recorded quarterly Cash from Operations of 16431000.0 in Q1 2026, down 37.31% quarter-over-quarter from 11966000.0 in Q4 2025, and up 2.13% year-over-year from 16087948.85 in Q1 2025.
Design Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 16431000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 2.13% year-over-year to 16431000.0; the TTM figure through Mar 2026 stood at 54000000.0 (down 13.79% YoY), while the FY2025 annual figure was 54358000.0, down 26.11% from the prior year.
- Cash from Operations came in at 16431000.0 for Q1 2026 at Design Therapeutics, down from 11966000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 9546000.0 in Q3 2024 to a low of 17424000.0 in Q1 2023.
- A 5-year average of 13163000.0 and a median of 12798000.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations slumped 219.91% in 2022 and jumped 34.32% in 2024, its largest moves.
- Design Therapeutics' Cash from Operations stood at 15091000.0 in 2022, then increased by 15.19% to 12798000.0 in 2023, then climbed by 22.96% to 9860000.0 in 2024, then retreated by 21.36% to 11966000.0 in 2025, then sank by 37.31% to 16431000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 16431000.0, 11966000.0, and 11162000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | -16.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.43 Mn |
| Mar 31, 2026 | -16.43 Mn |
| Dec 31, 2025 | -11.97 Mn |
| Dec 31, 2025 | -11.97 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Jun 30, 2025 | -14.44 Mn |
| Jun 30, 2025 | -14.44 Mn |
| Mar 31, 2025 | -16.79 Mn |
| Mar 31, 2025 | -16.79 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Sep 30, 2024 | -9.55 Mn |
| Sep 30, 2024 | -9.55 Mn |
| Jun 30, 2024 | -11.26 Mn |
| Jun 30, 2024 | -11.26 Mn |
| Mar 31, 2024 | -12.44 Mn |
| Mar 31, 2024 | -12.44 Mn |
| Dec 31, 2023 | -12.80 Mn |
| Dec 31, 2023 | -12.80 Mn |
| Sep 30, 2023 | -14.53 Mn |
| Sep 30, 2023 | -14.53 Mn |
| Jun 30, 2023 | -13.80 Mn |
| Jun 30, 2023 | -13.80 Mn |
| Mar 31, 2023 | -17.42 Mn |
| Mar 31, 2023 | -17.42 Mn |
| Dec 31, 2022 | -15.09 Mn |
| Dec 31, 2022 | -15.09 Mn |
| Sep 30, 2022 | -13.90 Mn |
| Sep 30, 2022 | -13.90 Mn |
| Jun 30, 2022 | -10.50 Mn |
| Jun 30, 2022 | -10.50 Mn |
| Mar 31, 2022 | -11.83 Mn |
| Mar 31, 2022 | -11.83 Mn |
| Dec 31, 2021 | -9.23 Mn |
| Dec 31, 2021 | -9.23 Mn |
| Sep 30, 2021 | -8.16 Mn |
| Sep 30, 2021 | -8.16 Mn |
| Jun 30, 2021 | -8.29 Mn |
| Jun 30, 2021 | -8.29 Mn |
| Mar 31, 2021 | -3.70 Mn |
| Mar 31, 2021 | -3.70 Mn |
| Dec 31, 2020 | -2.84 Mn |
| Dec 31, 2020 | -2.84 Mn |
| Sep 30, 2020 | -1.86 Mn |
| Sep 30, 2020 | -1.86 Mn |
| Jun 30, 2020 | -1.31 Mn |
| Jun 30, 2020 | -1.31 Mn |
| Mar 31, 2020 | -2.66 Mn |
| Mar 31, 2020 | -2.66 Mn |